CN117440964A - 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 - Google Patents
一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN117440964A CN117440964A CN202280035107.2A CN202280035107A CN117440964A CN 117440964 A CN117440964 A CN 117440964A CN 202280035107 A CN202280035107 A CN 202280035107A CN 117440964 A CN117440964 A CN 117440964A
- Authority
- CN
- China
- Prior art keywords
- polypeptide derivative
- pharmaceutically acceptable
- polypeptide
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 139
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 104
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 104
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract description 27
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title abstract description 27
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 title abstract description 23
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 title abstract description 23
- 230000008484 agonism Effects 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 9
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 5
- 230000002503 metabolic effect Effects 0.000 claims abstract description 4
- 229920005989 resin Polymers 0.000 claims description 41
- 239000011347 resin Substances 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 39
- 238000005859 coupling reaction Methods 0.000 claims description 31
- 238000010168 coupling process Methods 0.000 claims description 30
- 230000008878 coupling Effects 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 208000008589 Obesity Diseases 0.000 claims description 21
- 235000020824 obesity Nutrition 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 16
- 230000002194 synthesizing effect Effects 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 12
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 7
- 230000037406 food intake Effects 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 235000012631 food intake Nutrition 0.000 claims description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- 208000001280 Prediabetic State Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000020694 gallbladder disease Diseases 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 33
- 230000009977 dual effect Effects 0.000 abstract description 11
- 230000008685 targeting Effects 0.000 abstract description 9
- 230000004580 weight loss Effects 0.000 abstract description 5
- 208000016261 weight loss Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 26
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 24
- 235000002639 sodium chloride Nutrition 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 22
- BTSOGEDATSQOAF-SMAAHMJQSA-N tirzepatide Chemical compound CC[C@H](C)[C@@H](C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@@H](C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(NCC(NCC(N(CCC1)[C@@H]1C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC(C(C)(C)NC([C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](CC(C=C1)=CC=C1O)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](CC1=CC=CC=C1)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(O)=O)NC(C(C)(C)NC([C@H](CC(C=C1)=CC=C1O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O BTSOGEDATSQOAF-SMAAHMJQSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000009833 condensation Methods 0.000 description 17
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 16
- 230000005494 condensation Effects 0.000 description 16
- 229940121512 tirzepatide Drugs 0.000 description 16
- 108091004331 tirzepatide Proteins 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 239000013641 positive control Substances 0.000 description 13
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 11
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 11
- -1 2- (2- (fluorenylmethoxycarbonyl-2-aminoethoxy) ethoxy) acetic acid Chemical compound 0.000 description 10
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 10
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000012670 alkaline solution Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 6
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- GOPWHXPXSPIIQZ-FQEVSTJZSA-N (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C)C3=CC=CC=C3C2=C1 GOPWHXPXSPIIQZ-FQEVSTJZSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000011097 chromatography purification Methods 0.000 description 5
- 210000002468 fat body Anatomy 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- XQPYRJIMPDBGRW-UHFFFAOYSA-N 2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCC(=O)O)C3=CC=CC=C3C2=C1 XQPYRJIMPDBGRW-UHFFFAOYSA-N 0.000 description 4
- TZCYLJGNWDVJRA-UHFFFAOYSA-N 6-chloro-1-hydroxybenzotriazole Chemical compound C1=C(Cl)C=C2N(O)N=NC2=C1 TZCYLJGNWDVJRA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 4
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100040918 Pro-glucagon Human genes 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 229940038384 octadecane Drugs 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CQWXKASOCUAEOW-UHFFFAOYSA-N 2-[2-(carboxymethoxy)ethoxy]acetic acid Chemical compound OC(=O)COCCOCC(O)=O CQWXKASOCUAEOW-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical group CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- AJDPNPAGZMZOMN-UHFFFAOYSA-N diethyl (4-oxo-1,2,3-benzotriazin-3-yl) phosphate Chemical compound C1=CC=C2C(=O)N(OP(=O)(OCC)OCC)N=NC2=C1 AJDPNPAGZMZOMN-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- JJOJFIHJIRWASH-UHFFFAOYSA-N icosanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCCCC(O)=O JJOJFIHJIRWASH-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000002473 insulinotropic effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical class [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- ZEQLLMOXFVKKCN-AWEZNQCLSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(OC(C)(C)C)C=C1 ZEQLLMOXFVKKCN-AWEZNQCLSA-N 0.000 description 1
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101150020692 Gipr gene Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229940126705 Mounjaro Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000004490 abdominal subcutaneous fat Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种GLP‑1R和GIPR双重靶向激动作用的多肽衍生物及其制备方法和用途,如式(Ⅰ)所示,(Ⅱ)为肽链的支链修饰结构。所述多肽衍生化合物及其药学上可接受的盐可用于治疗糖尿病、减肥、NASH等代谢性相关疾病、神经退行性疾病等领域。Tyr‑Aib‑Asp‑Gly‑Thr‑Phe‑Thr‑Ser‑Asp‑Tyr‑Ser‑Ile‑Xaa13‑Leu‑Asp‑Lys‑Ile‑Ala‑Gln‑Xaa20‑Glu‑Phe‑Val‑Gln‑Trp‑Leu‑Leu‑Ala‑Gly‑Gly‑Pro‑Ser‑Ser‑Gly‑Ala‑Pro‑Pro‑Pro‑Ser‑NH2(Ⅰ)
Description
本发明属于医药技术领域,尤其涉及一种作为GLP-1R和GIPR双重靶向激动作用的多肽衍生物及其制备方法和用途。
葡萄糖依赖性促胰岛素多肽(抑胃多肽,GIP,Gastric Inhibitor Polypeptide)是一种42个氨基酸组成的多肽,由主要位于近端小肠的K细胞分泌,是第一个被发现的肠促胰素。在早期的研究中,T2DM患者急性输注GIP引发的促胰岛素分泌效应减弱,限制了其作为药物开发靶点的可能性。但近年来的研究发现,T2DM患者在接受降糖药物治疗,改善血糖控制后,GIP的促胰岛素作用可以得到恢复。此外,GIP能作用于骨和脂肪组织,抑制骨的重吸收,并促进脂肪细胞的脂质合成,进而影响脂代谢与脂肪分布,其效应独立于胰岛素作用;GIP还可能通过激活下丘脑中的GIPR+神经元,减少食物摄入,减轻体重;GIP治疗小鼠的学***上升、和阿尔茨海默症相关的淀粉样蛋白数量减少、慢性炎症和氧化应激减少、神经细胞凋亡速度减慢。
胰高血糖素样肽-1(GLP-1,Glucagon-like peptide 1)是由人肠道L细胞分泌的一种肽类激素,能够促进胰岛素的分泌、抑制胰高血糖素的分泌,具有降低血糖浓度的功效,被用于II型糖尿病的治疗。GLP-1通过与其特异性受体GLP-1R结合发挥生理效应,而GLP-1R广泛分布于全身多个器官或组织,循证医学证据也证实GLP-1R激动作用(GLP-1RA)除了治疗糖尿病和肥胖外,对心血管***、肾脏、中枢神经***均有保护作用。GLP-1R分布广泛,可以与其他受体共同调节关键靶组织的代谢。
然而天然GLP-1和GIP在体内不稳定,易被二肽基肽酶-IV(DPP-IV)快速降解。
礼来制药公司的Tirzepatide(LY3298176)作为GLP-1R和GIPR双重靶向激动作用的新药正在进行各种适应症的临床三期研究。2022年5月14日,FDA批准礼来(Eli Lilly)公司开发的Mounjaro(tirzepatide)上市,用于与控制饮食和锻炼联用,改善成人2型糖尿 病患者的血糖控制。其它双靶点作用的多肽新药也在研究中,如CN105849122A、CN104470948A、CN105209485A等等。
已有的研究结果发现,GLP-1R和GIPR双重靶向激动活性的合理搭配是此类药物的核心,不同的活性搭配产生了不同的药理作用与不良反应。同时不同的支链修饰对这类GLP-1R和GIPR双重靶向激动活性和药效半衰期等产生不同的效果。本领域仍然渴望对GLP-1R和GIPR双重靶向激动作用的多肽在治疗糖尿病、减肥、心血管合并糖尿病、NASH、神经退行性疾病如AD和PD等具有巨大的治疗潜能。
发明内容
本发明的目的在于通过深入的研究和创造性的劳动,发现一种GLP-1R和GIPR双重靶向激动作用的多肽衍生物或其盐以及对应的药物组合物,其体内长效性远远超过同类多肽化合物,同时有效剂量下在某些方面具有明显更强的药物活性与更好的临床价值,使其在治疗糖尿病、减肥、心血管合并糖尿病、代谢综合征、NASH、神经退行性疾病如AD和PD等领域具有巨大的潜能。
本发明提供了一种GLP-1R和GIPR双重靶向激动作用的多肽衍生物或其盐,所述GLP-1R和GIPR双重靶向激动作用的多肽衍生物为式(I)所示,主链中Xaa
20为Lys且其侧链ε-氨基以酰胺键形式连接支链(II)式中的X
1;
Tyr-Aib-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Xaa
13-Leu-Asp-Lys-Ile-Ala-Gln-Xaa
20-Glu-Phe-Val-Gln-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH
2
(Ⅰ)
其中,Aib为氨基异丁酸,与前后氨基酸以酰胺键(肽键)连接;
Xaa
13为Aib,Tyr或Ala;
另有,(II)式中n为16或18;X
1与X
2同时为
或X
2为
同时X
1为
在本发明的一种实施方案中,所述多肽衍生物中,(II)式中n为16。
在本发明的一种实施方案中,所述多肽衍生物中,(II)式中n为18
在本发明的一种实施方案中,所述多肽衍生物中,(II)式中X
1与X
2同时为
在本发明的一种实施方案中,所述多肽衍生物中,(II)式中X
2为
同时X
1为
在本发明的一种实施方案中,所述多肽衍生物为下列式(1):
在本发明的一种实施方案中,所述多肽衍生物为下列式(2)
在本发明的一种实施方案中,所述多肽衍生物为下列式(3)
Y(Aib)DGTFTSDYSI(Aib)LDKIAQKAFVQWLLAGGPSSGAPPPS-NH2
在本发明的一种实施方案中,所述多肽衍生物为下列式(4)
在本发明的一种实施方案中,所述多肽衍生物为下列式(5)
在本发明的一种实施方案中,所述多肽衍生物为下列式(6)
在本发明的一种实施方案中,所述多肽衍生物为下列式(7)
在本发明的一种实施方案中,所述多肽衍生物为下列式(8)
在本发明的一种实施方案中,所述多肽衍生物为下列式(9)
在本发明的一种实施方案中,所述多肽衍生物为下列式(10)
在本发明的一种实施方案中,支链(II)式中谷氨酰胺为(L)-构型。
本发明的化合物可以存在特定的几何或立体异构体形式。本发明设想所有的这类化合物,包括顺式和反式异构体、(-)-和(+)-对映体、(R)-和(S)-对映体、非对映异构体、(D)-异构体、(L)-异构体,及其外消旋混合物和其他混合物,例如对映异构体或非对映体富集的混合物,所有这些混合物都属于本发明的范围之内。所有这些异构体以及它们的混合物,均包括在本发明的范围之内。在本发明的实施方案中,作为本发明的优选实施方式,所述的多肽衍生物其中的氨基酸优选为L型氨基酸。
除非天然氨基酸外,文中表述的天然氨基酸均为国际通用单字母或三字母缩写,如S或Ser代表丝氨酸,P或Pro代表脯氨酸等。
另一方面,本发明提供了一种上述多肽衍生物的制备方法,所述的制备方法包括如下步骤A:
1)固相或液相法合成支链片段;
2)固相法合成肽链;
3)将支链片段与肽树脂偶联;
4)裂解除去保护基团与树脂挂载,得到多肽衍生物。
本发明提供了另一种上述多肽衍生物的制备方法,所述的制备方法包括如下步骤B:
1)固相法合成肽链;
2)固相法将支链各模块逐次与肽树脂偶联;
3)裂解除去保护基团与树脂挂载,得到多肽衍生物。
在一些实施例中,所述具体制备过程步骤A描述如下:
1)固相或液相法合成支链片段;
在一些实施例中,所述合成支链片段的方案如下所示:
将Fmoc-AEEA-OH(2-(2-(芴甲氧羰基-2-氨基乙氧基)乙氧基)乙酸缩合偶连到2-CTC树脂上;Pip(哌啶)/DMF(N,N-二甲基甲酰胺)溶液或其它碱性溶液脱Fmoc保护;将第二个Fmoc-AEEA-OH缩合偶联到树脂上;Pip(哌啶)/DMF(N,N-二甲基甲酰胺)溶液或其它碱性溶液脱Fmoc保护;将Fmoc-Glu-OtBu缩合偶联到树脂上;tBu基团单保护的十八烷二酸偶联到树脂上;采用1%TFA(三氟乙酸)的DCM溶液将片段切落,暴露出需要与肽链结合的羧基。
在一些实施例中,所述合成支链片段的方案如下所示:
X
1为
X
2为
Xaa
20为K挂载支链时,
将
与
在弱有机碱条件下缩合偶联,TFA脱除Boc保护;将Fmoc-Glu-OtBu与前一步产物缩合偶联,Pip溶液或其它碱性溶液脱Fmoc保护;tBu基团单保护的十八烷二酸缩合偶联到前一步Glu的氨基位置;最后采用钯碳催化作用下氢气水解脱除苄酯,暴露出需要与肽链结合的羧基。
2)固相法合成肽链;
在一些实施例中,所述合成主链的方案如下所示:
按本发明分子结构的氨基酸顺序将Fmoc保护氨基酸依次逆序偶联到固相合成树脂上,Pip溶液或其它碱性溶液去保护Fmoc,循环直至肽链主链氨基酸全部完成;其中将待连接侧链片段的的Lys采用Alloc保护(可选地,采用原料Fmoc-Lys(Alloc)-OH)或Dde保护(可选地,采用原料Fmoc-Lys(Dde)-OH);本发明分子结构的末端丝氨酰胺,采用Rink Amide-AM树脂、Rink Amide-MBHA树脂、Sieber树脂、PAM树脂、Rink Amide树脂等可构建酰胺型氨基酸的树脂。
3)将支链片段与肽树脂偶联;
在一些实施例中,所述支链与肽链偶联的方案如下:
脱肽树脂Lys侧链保护,如Xaa
20为侧链保护基为Alloc时,采用四(三苯基膦)钯和PhSiH
3脱去的Alloc保护;如Xaa
20为侧链保护基为Dde时,采用水合肼脱去的Dde保护;将支链片段与肽树脂偶联;Pip溶液或其它碱性溶液脱首位氨基酸Fmoc保护。
4)裂解除去保护基团与树脂挂载
裂解切割除去保护基团与树脂挂载,得到双靶点多肽衍生物粗品。
在一些实施例中,所述裂解的方案如下:
按一定比例配制TFA裂解液,将全保护肽树脂加入裂解液,从树脂上切割下来并脱除侧链。真空旋蒸除去TFA,将醚类或烷烃类溶剂加入浓缩液析出白色固体即目标产物。
可选地,进一步包括:
5)色谱纯化:进行多步反相色谱纯化或离子色谱纯化,最后转盐成某种酸的盐溶液或游离型溶液;和6)冻干。
在一些实施例中,所述步骤B合成主链的方案与步骤A合成主链的方案相同,首位氨基酸Tyr采用Boc保护氨基端。
在一些实施例中,所述步骤B固相法将支链各模块逐次与肽树脂偶联的方案如下:
该步骤采用多肽固相合成的方式进行,按本发明支链各模块结构顺序依次逆序连接到树脂上的多肽主链。先脱去Xaa
20的侧链保护,将X
1连接到Xaa
20,将X
2连接到X
1,将谷氨酸侧链连接到X
2,最后连接十八烷(或二十烷)二酸单叔丁酯完成整个支链的上载与合成。
如X
1和X
2为
结构,Xaa
20为K挂载支链时,
采用四(三苯基膦)钯和PhSiH
3脱去主肽链Xaa
20(Lys)的Alloc保护或采用水合肼脱去的Dde保护;用缩合试剂激活Fmoc-AEEA-OH(X
1)的羧酸,缩合偶联到肽链,Pip溶液或其它碱性溶液脱Fmoc保护;用缩合试剂激活Fmoc-AEEA-OH(X
2)的羧酸,缩合偶联到X
1,Pip溶液或其它碱性溶液脱首位氨基酸Fmoc保护;用缩合试剂将Fmoc-Glu-OtBu的羧酸激活,缩合偶联到X
2,Pip溶液或其它碱性溶液脱Fmoc保护;tBu基团单保护的十八烷(或二十烷)二酸缩合偶联到Glu的α氨基位置;至此完成整个支链的上载与合成。
如X
1为
X
2为
Xaa
20为K挂载支链时,
采用四(三苯基膦)钯和PhSiH
3脱去主肽链X
2(Lys)的Alloc保护或采用水合肼脱去的Dde保护;缩合试剂预活化3,6-二氧杂-辛二酸(X
1),然后与主肽链反应偶联上载;然后加入Fmoc单保护的3,6-二氧杂-1,8-辛二胺(X
2)缩合偶联;Pip/DMF溶液或其它碱性溶液脱去X
2的Fmoc保护;缩合试剂预活化Fmoc-Glu-OtBu,再缩合偶联;Pip/DMF溶液或其它碱性溶液脱Fmoc保护;tBu基团单保护的十八烷(或二十烷)二酸缩合偶联到Glu的α氨基位置;至此完成整个支链的上载与合成。
文中所述缩合偶联是指羧酸与氨基的缩合偶联反应,可根据具体情况(如固相法多肽合成)使用DCC/HOBt,DIC/Cl-HOBt,TBTU/DIEA,HBTU/DIEA,PyBOP/DIEA,EDC/HOBt,HATU/DIEA,T3P/DIEA,DEPBT/TEA等有机合成中的缩合剂。
文中部分缩写符号释义如下所示。
2-CTC树脂:
Sieber树脂:
Rink Amide-AM树脂:
Fmoc:芴甲氧羰基
EDC:1-(3-二甲胺基丙基)-3-乙基碳二亚胺
DIC:N,N'-二异丙基碳二亚胺
HOBt:1-羟基苯并三氮唑
DCC:N,N'-二环丙基碳二亚胺
Cl-HOBt:6-氯-1-羟基苯并三氮唑
HBTU:O-苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐
TBTU:O-苯并三氮唑-N,N,N',N'-四甲基脲四氟硼酸酯
PyBop:六氟磷酸苯并***-1-基-氧基三吡咯烷基磷
HATU:2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
TIS:三异丙基硅烷
DIEA:二异丙基乙胺
Pip:哌啶(六氢吡啶)
OtBu:叔丁酯
DCM:二氯甲烷
MTBE:甲基叔丁基醚
Et
2O:***
NMP:N-甲基吡咯烷酮
Bzl:苄基
TEA:三乙胺
DEPBT:3-(二乙氧基磷酰氧基)-1,2,3-苯并三嗪-4-酮
Dde:1-(4,4-二甲基-2,6-二氧代环己亚基)乙基
T3P:1-丙基磷酸酐
Alloc:烯丙氧羰基
tBu:叔丁基
Pd[P(C
6H
5)
3]
4:四(三苯基膦)钯
PhSiH
3:苯基硅烷
第三方面,本发明公开了一种药物组合物,其包含本发明所述的化合物或其药学上可 接受的盐为活性成分或主要活性成分,以及药学上可接受的载体。
构成本发明的一部分是药学上可接受的盐,适当的“药学上可接受的盐”包括本发明的游离型化合物、无机酸或有机酸反应形成的本发明化合物的常规无毒盐、无机碱或有机碱反应形成的本发明化合物的常规无毒盐。例如,包括得自无机酸例如盐酸、氢溴酸、硫酸、磷酸、硝酸等的盐,也包括得自有机酸例如乙酸、丙酸、琥珀酸、乙醇酸、硬脂酸、乳酸、苹果酸、酒石酸、柠檬酸、抗坏血酸、马来酸、羟基马来酸、苯乙酸、谷氨酸、苯甲酸、水杨酸、对氨基苯磺酸、富马酸、甲苯磺酸、甲磺酸、乙烷二磺酸、草酸、羟乙基磺酸、三氟乙酸等的盐。又例如,包括得自无机碱例如钠、钾、钙、镁、锌、铁等的盐,也包括得自有机碱例如氨水、精氨酸、赖氨酸、瓜氨酸、组氨酸等的盐。本发明陈述的盐包括因药学目的而采用的少量酸或碱化合物反应形成的含酸或碱的盐。药学上可接受的盐优选为含钠的盐。
本发明的其中一个目标是根据本发明的GLP-1R和GIPR双重靶向激动作用的多肽衍生物研究开发成为临床可用的药物制剂。该制剂可进一步包含缓冲剂、防腐剂、等渗剂、助溶剂、张度剂、螯合剂、稳定剂、抗氧化剂、表面活性剂、酸碱调节剂等。浓度通常为0.01mg/ml至50mg/ml,其中所述的制剂具有3.0至9.0的pH。
在本发明的一个实施方案中,药物制剂是含水制剂,即水溶液,通常是溶液、乳液或混悬液。
在另一个实施方案中,药物制剂是一种冻干制剂,在使用前加入溶剂和/或稀释剂至其中充分溶解后备用。
在另一个实施方案中,药物制剂是不需预先溶解的即用型干燥制剂,例如喷雾吸入冻干粉等。
在本发明的另一个实施方案中,药物制剂pH值的范围选择至关重要,会影响到GLP-1R和GIPR双重靶向激动作用的多肽衍生物的溶解性和稳定性,在某些特定条件下会产生多肽物理性聚集或吸附。在本发明的一个实施方案中,药物制剂的pH值为3.0~5.0。在本发明的一个实施方案中,药物制剂的pH值为7.0~8.0。在本发明的一个实施方案中,药物制剂的pH值为7.5~8.5。在本发明的另一个实施方案中,药物制剂的pH值为5.0~7.5。
在本发明的进一步实施方案中,缓冲剂选自磷酸氢二钠、乙酸钠等,防腐剂选自苯酚、邻甲酚、间甲酚、对甲酚等,等渗剂选自氯化钠类盐、糖或糖醇、氨基酸、丙二醇、甘露 醇等,助溶剂选自甘露醇、丙二醇、PEG、甘油、吐温、乙醇等,张度剂选自氯化钠类盐、丙二醇、甘油、甘露醇等,螯合剂选自EDTA、柠檬酸盐等,稳定剂选自肌酐、甘氨酸、烟酰胺、PEG等,抗氧化剂选自亚硫酸氢钠、亚硫酸钠、半胱氨酸、甲硫氨酸等,表面活性剂选自聚山梨酯、甘油、甘露醇等,酸碱调节剂选自盐酸、磷酸、硫酸、氢氧化钠、氢氧化钾等。
其它成分可根据药物制剂的需要(例如长期稳定性)存在于本发明的多肽衍生物的药物制剂中,包括乳化剂、金属离子、油质载体、蛋白质(如人血清白蛋白、明胶或蛋白质等)以及两性离子(例如精氨酸、甘氨酸、赖氨酸、组氨酸、甜菜碱和牛磺酸等)等和其它药用制剂添加剂。
术语“药学上可接受的载体”是指能够递送本发明有效量活性物质、不干扰活性物质的生物活性并且对宿主或者患者无毒副作用的任何制剂载体或介质,代表性的载体包括水、油、脂质体等。
针对药物或药理学活性剂而言,术语“有效量”或“治疗有效量”是指无毒的但能达到预期效果的药物或药剂的足够用量。
术语“活性成分”、“治疗剂”,“活性物质”或“活性剂”是指一种化学实体,它可以有效地治疗目标紊乱、疾病或病症。
“任选”或“任选地”指的是随后描述的事件或状况可能但不是必需出现的,并且该描述包括其中所述事件或状况发生的情况以及所述事件或状况不发生的情况。
第四方面,本发明所述的GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐在预防和或治疗疾病中的用途,其优选的技术方案,所述疾病包括代谢综合征、肥胖、糖尿病、肥胖相关疾病和糖尿病相关疾病。糖尿病包括以因胰岛素分泌、胰岛素作用或其二者的缺陷引起的高血糖为特征的一组代谢疾病。根据病症机理将糖尿病分为Ⅰ型糖尿病、Ⅱ型糖尿病和妊娠糖尿病。
本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐,可将GIP的作用(例如,对脂肪代谢和体重减轻以及血糖的作用)与GLP-1的作用(例如,对血糖水平和食物摄取的作用)组合。因此,其可用于加速消除过量的脂肪组织,引起持续的体重减轻,并改善血糖控制。GLP-1R和GIPR双重靶向激动作用还可用于降低心血管风险因素,例如高胆固醇,如高LDL胆固醇。
本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐,还可用于治疗胰岛素抵抗、糖耐量受损、前驱糖尿病、空腹血糖升高、Ⅱ型糖尿病、高血压、血脂异常(或这些代谢风险因素的组合)、动脉粥样硬化、动脉硬化、冠心病、外周动脉疾病和卒中。这些都是可能与肥胖有关的病症。但是,本发明所述使用的化合物对这些病症的作用可通过对体重的作用来全面或部分地介导,或者可独立于所述作用。
在某些实施方案中,本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐可在如肥胖相关炎症、肥胖相关胆囊疾病和肥胖诱发的睡眠呼吸暂停等肥胖相关疾病起到治疗作用。
作为优选,还包括在制备治疗II型糖尿病药效延迟和/或预防II型糖尿病恶化的药物中的应用,以及改善II型糖尿病成人中血糖控制的方法、包括向有需要的患者施用有效量的上述多肽衍生物作为饮食和运动补充的应用。
本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐,对于与多个代谢相关的因素有关、发病机理复杂的NASH有积极预防与治疗意义。胰岛素抵抗及脂肪代谢紊乱构成了早期对肝脏的损伤,从而在肝脏细胞内形成脂肪堆积(NAFLD)。随着疾病的发展,机体免疫调节的形成,肝脏细胞产生炎症反应,继而推动形成纤维化,最终导致肝硬化等终末期肝病症状。而本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物能有效调节血糖水平参与代谢,对于NASH可全面或部分地介导,或者可独立于所述作用。
本发明所述代谢综合征可以是糖尿病或糖尿病相关疾病,或者肥胖或肥胖相关疾病,或者NAFLD、NASH或相关疾病。肥胖、糖尿病之间的联系是众所周知的,因此这些病症并非独立或互相排斥的,而是可能结合在一起。NAFLD、NASH或相关疾病因为机理复杂但也涉及并相关肥胖与糖尿病,可能并非独立或互相排斥的。
本发明所述GLP-1R和GIPR双重靶向激动作用多肽衍生物与其药学上可接受的盐,对于神经退行性疾病如AD(阿尔茨海默综合症)或PD(帕金森综合症)的预防与治疗有积极意义。
第五方面,本发明实验研究发现,本发明的GLP-1R和GIPR双重靶向激动多肽衍生物在现有技术上通过保守或非保守氨基酸替换与支链修饰后出人意料地具有非常好的体内长效性,其半衰期显著优于对照药物Tirzepatide且有统计学意义。对照药物Tirzepatide 已公开数据显示其人体临床平均半衰期为5.0天,按本实验SD大鼠药代实验结果可推导多肽衍生物(1)的人体半衰期为7.88天,意即可实现患者半个月给药一次,极大地方便临床应用。
第六方面,本发明实验研究发现,本发明所述GLP-1R和GIPR双重靶向激动多肽衍生物在现有技术上通过保守或非保守氨基酸替换与支链修饰后能有效激活GIPR和GLP-1R,起到双靶点激动活性与适宜的活性搭配以及药效作用,与对照药物Tirzepatide药效作用相似,并意外地发现某些活性药效作用明显强于Tirzepatide且有统计学意义,如TC(总胆固醇)的降低。
实施例1制备多肽衍生物(1)
MALDI-TOF-MS:[M+H]4800.51
1)液相法合成支链片段;
将
与
在三乙胺条件下使用氯甲酸异丁酯缩合偶联,TFA脱除Boc保护;将Fmoc-Glu-OtBu与前一步产物用TBTU/DIEA缩合偶联,20%Pip/NMP溶液脱Fmoc保护;tBu基团单保护的十八烷二酸缩合偶联到前一步Glu的氨基位置;最后采用钯碳催化氢气水解脱除苄酯,得到支链片段。
2)固相法合成肽链;
选用Rink Amide-MBHA树脂按多肽衍生物(1)肽链氨基酸序列从C端到N端逆序将Fmoc保护氨基酸依次偶联到固相合成树脂上,20%Pip/NMP溶液脱保护Fmoc,循环直 至GLP-1主链氨基酸全部完成;其中将待连接支链片段的的Lys缩合到肽树脂上时选用Fmoc-Lys(Dde)-OH。
3)将支链片段与肽树脂偶联;
采用2%水合肼/乙醇胺溶液脱去的Dde保护;将步骤1)侧链片段与步骤2)肽树脂使用缩合剂HATU/DIEA偶联;20%Pip/DMF溶液脱首位氨基酸Fmoc保护。
4)裂解除去保护基团与树脂挂载,
按一定比例(TFA:TIS:H
2O:EDT=96:2:1:1)配制裂解液,将全保护肽树脂加入裂解液,将目标化合物从树脂上切割下来并脱除侧链。真空旋蒸除去TFA,将Et
2O加入浓缩液析出白色固体即目标产物粗品。
5)色谱纯化
进行多步反相色谱纯化或离子色谱纯化,最后转盐成含钠的盐溶液;
6)冻干
冻干后得到三氟乙酸多肽衍生物(1)白色或类白色疏松状固体。
实施例2制备多肽衍生物(1)
MALDI-TOF-MS:[M+H]4800.53
1)固相法合成肽链;
按多肽衍生物(1)肽链的氨基酸序列将Fmoc保护氨基酸依次逆序偶联到Rink Amide-AM树脂上,缩合偶联试剂采用PyBOP/DIEA或DIC/Cl-HOBt,20%哌啶/DMF溶液脱保护Fmoc,循环直至氨基酸全部完成肽链;其中待连接侧链片段的Lys为Alloc保护,即Fmoc-Lys(Alloc)-OH。首位氨基酸Tyr位置选用Boc-Tyr(tBu)-OH。
2)固相法将支链各模块逐次与肽树脂偶联;
四(三苯基膦)钯Pd[P(C
6H
5)
3]
4和苯基硅烷PhSiH
3/DMF溶液脱肽树脂Lys侧链Alloc 保护;采用HATU/DIEA预先激活3,6-二氧杂辛二酸,然后与肽树脂偶联上载;加入Fmoc单保护的3,6-二氧杂-1,8-辛二胺缩合偶联;20%Pip/DCM脱去Fmoc保护;缩合剂HATU/DIEA预活化Fmoc-Glu-OtBu,再缩合偶联;20%Pip/DCM脱去Fmoc保护;tBu基团单保护的二十烷二酸缩合偶联到Glu的α氨基位置完成整个支链的上载与合成。
3)裂解除去保护基团与树脂挂载,得到多肽衍生物。
按一定比例(TFA:TIS:H
2O:苯酚=96:1.5:1.5:1)配制裂解液,将全保护肽树脂加入裂解液,将目标化合物从树脂上切割下来并脱除侧链。真空旋蒸除去TFA,将MTBE加入浓缩液析出白色固体即目标产物粗品。
4)色谱纯化
进行多步反相色谱纯化纯化,最后转盐成醋酸的盐溶液;
5)冻干
冻干后得到醋酸多肽衍生物(1)白色或类白色疏松状固体。
参考实施例1与实施例2与专利中所述的合成步骤分别合成了发明中所述部分其它化合物:
多肽衍生物(2)MALDI-TOF-MS:[M+H]4878.59;
多肽衍生物(3)MALDI-TOF-MS:[M+H]4786.52;
多肽衍生物(4)MALDI-TOF-MS:[M+H]4772.41;
多肽衍生物(5)MALDI-TOF-MS:[M+H]4786.44;
多肽衍生物(6)MALDI-TOF-MS:[M+H]4864.55;
多肽衍生物(7)MALDI-TOF-MS:[M+H]4786.56;
多肽衍生物(8)MALDI-TOF-MS:[M+H]4800.57;
多肽衍生物(9)MALDI-TOF-MS:[M+H]4864.50;
多肽衍生物(10)MALDI-TOF-MS:[M+H]4786.43。
实施例3 SD大鼠药代实验
多肽化合物(1)与Tirzepatide在雄性大鼠体内单剂量皮下给药后,于不同时间点采 集血样,用LC-MS/MS测定血浆中化合物的浓度并计算相关药代参数,考察化合物在大鼠体内药代动力学特征。
16只雄性SD大鼠按体重随机分为2组,每组8只。给药前1天禁食不禁水12~14h,给药后4h给食。
样品采集。于给药前及给药后异氟烷麻醉经眼眶取血0.1ml,置于EDTAK2离心管中并放置冰浴上。5000rpm,4℃离心10min,收集血浆。
SC组采血时间点:0,5,15,30min,1,2,4,6,8,24,28,32,48h,分析检测前,所有血浆样品存于-80℃。
数据采集及控制***软件为Analyst1.5.1软件(Applied Biosystem)。图谱样品峰积分方式为自动积分;采用样品峰面积和内标峰面积的比值作为指标,和样品的浓度进行回归。回归方式:线性回归,权重系数为1/X
2。药代动力学参数用WinNonlin Professional v6.3(Pharsight,USA)用非房室模型分析处理。C
max为实测的最大血药浓度,血药浓度-时间曲线下面积AUC
(0→t)由梯形法计算得到,T
max为给药后血药浓度达峰时间。实验数据用“均数±标准差”(Mean±SD,n≥8)或“均数”(Mean,n=8)表示。
根据血药浓度数据,使用WinNonlin V6.3非房室模型计算给药后的药代参数,见下表。
多肽化合物(1)组
Tirzepatide组
实施例4ob/ob小鼠降糖、减重降脂实验
32只ob/ob小鼠根据空腹体重,空腹血清TC、LDL,均衡随机分成4组,分别为模型对照组,受试样品组(1.35mg/kg)和阳性对照组(Tirzepatide,1.35mg/kg),每组8只。另8只常规饲喂小鼠设为正常对照组(溶媒)。
每3天背部皮下注射给药1次,共给药8次(D0、D3、D6、D9、D12、D15、D18、D21),模型对照组和正常对照组按生理盐水0.15mL/20g的剂量给药,受试样品组和阳性对照组按0.312mg/kg的剂量给药。
1)体重:分组前禁食不禁水12h测定1次,根据体重和TC、LDL均衡随机分组。分组后自D0始,每天测定1次。
2)Lee’s指数:首次给药前和D23各测定1次体长。体长为鼻尖至***的最大直线长度。调整小鼠***使其身体呈舒展状态,用直尺刻度读出小鼠体长。
Lee’s指数=[体重(g)×10
3/体长(cm)]
1/3。
3)血液中葡萄糖(GLU)的测定:每3天测定一次。
4)血液生化(TG、TC、LDL、HDL):分别在分组前、D11和D23各测定一次。
5)脂肪-体重系数:小鼠安乐死后,摘取腹部皮下脂肪、性腺周围脂肪,肩胛骨皮下脂肪并分别称重,计算脂肪-体重系数。
6)摄食量、饮水量:自D0始,每天测定1次(有禁食操作时除外)。
实验结果如下:
1)体重:
多肽化合物(1)组初始体重较模型对照组低(D0,p<0.05),与Tirzepatide组无统计学差异。从D1开始,多肽化合物(1)和Tirzepatide组动物体重均出现下降,且实验期间(D1-D23)体重增长缓慢,均显著低于模型对照组(p<0.01);多肽化合物(1)组体重平均值略高于Tirzepatide组,但无统计学差异。
实验动物体重记录表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
2)Lee’s指数
Lee’s指数是反应大鼠肥胖程度的有效指标,所有动物的Lee’s指数均有增加,正常组动物增加最少。与模型对照组相比,各给药组动物Lee’s指数略有降低。结果说明受试药与阳性对照药对于ob/ob小鼠的肥胖均能起到抑制作用,受试组药物与阳性对照药的控制能力接近,无统计学差异。
动物Lee’s指数表
3)随机血糖:
动物在给药后第三天进行初次血糖测定,结果表明各给药组动物的血糖浓度与正常组相比明显降低,在D0-D10期间血糖浓度控制良好。实验期间,动物血糖浓度逐渐上升,可能与其年龄和体重增加有关。与模型对照组相比,正常对照组动物D14-D23血糖值明显低于模型对照组小鼠,表明ob/ob小鼠的基础血糖值较高。与模型对照组小鼠相比,D3-D23受试药与阳性对照药均有不同程度明显的降血糖作用。给药组与阳性对照药(多肽化合物(1)/Tirzepatide)相比无显著差异。
实验动物血糖变化表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
4)血液生化
(1)TC:实验开始前(D0)多肽化合物(1)与模型组相较其他同品系小鼠组初始数值较高。与自身给药后不同时间相比,给药后多肽化合物(1)与Tirzepatide组肥胖小鼠的TC降低明显,说明此受试药与阳性对照药能够显著的降低TC含量。从D11和D23的结果可以看出,多肽化合物(1)降低TC的能力与Tirzepatide相似。且多肽化合物(1)组在初始值较高的情况下,降低TC的能力较强在D23时接近Tirzepatide组水平,且统计学意义从##p<0.01到#p<0.05显著改善。
(2)TG:实验开始前(D0)多肽化合物(1)和Tirzepatide相较其他同品系小鼠组初始数值较低。与自身给药后不同时间相比,给药后多肽化合物(1)与Tirzepatide组肥胖小鼠的TG降低明显,说明此受试药与阳性对照药能够显著的降低TG含量。D23,多肽化合物(1)降低TG的能力与Tirzepatide相似(多肽化合物(1)vs Tirzepatide,p<0.01)。
(3)LDL:实验开始前(D0)多肽化合物(1)和Tirzepatide相较其他同品系小鼠组初始数值较高。与自身给药后不同时间相比,给药后D11和D23,多肽化合物(1)与Tirzepatide组肥胖小鼠的LDL水平均明显降低,且显著低于模型对照组(p<0.01),多肽化合物(1)和Tirzepatide组间比较未见统计学差异。
(4)HDL:实验进行期间,模型对照组小鼠HDL水平均高于正常对照组小鼠。给药前(D0)同品系小鼠HDL水平较为接近。相比于模型对照组,给药后D11和D23,受试组与阳性对照药组均能显著降低HDL水平。
上述结果说明,受试药与阳性对照药物均能降低动物的TG、TC、LDL和HDL浓度。
动物血液TC含量变化表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
动物血液TG含量表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
动物血液LDL含量表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
动物血液HDL含量表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
5)脂肪-体重系数
在给药23天后,解剖小鼠,分离不同部位脂肪,并根据公式(脂肪/体重×100)计算脂肪-体重系数。由结果可知,模型对照组小鼠各部位脂肪-体重系数均显著高于正常对照组小鼠。多肽化合物(1)能显著降低ob/ob小鼠腹部皮下和性腺周围的脂肪,且效果与阳性对照药物Tirzepatide无明显差异。此外,药物对于肩胛骨皮下脂肪-体重系数无影响。
脂肪-体重系数表
与模型对照组相比,*p<0.05,**p<0.01;与对应的阳性药相比,#p<0.05,##p<0.01。
6)摄食量、饮水量
给药后动物的进食量明显下降,动物整体进食趋势与给药频率呈现了一定相关性,表现为给药当天进食量最低,随着时间推移,进食量缓慢增加,但整体增加量低于模型对照组与正常对照组。在实验后期动物的进食量整体增加,可能与动物年龄和体重增加有关。实验结果说明,受试药与阳性对照药均有明显的摄食控制作用。
各组实验动物的饮水差异较大,给药组低于正常组与模型对照组。能明显观察动物给药后饮水量降低,首次给药后作用最为明显。D11各组动物饮水量均明显增加可能与后续禁食操作有关,但各组小鼠的饮水量都有增加。实验结果说明,受试药与阳性对照药均有明显的饮水控制作用。
Claims (12)
- 一种如(I)所示的多肽衍生物,或几何异构体,或立体异构体、或其药学上可接受的盐,主链中Xaa 20为Lys且其侧链ε-氨基以酰胺键形式连接支链(II)式中的X 1;Tyr-Aib-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Xaa 13-Leu-Asp-Lys-Ile-Ala-Gln-Xaa 20-Glu-Phe-Val-Gln-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH 2(Ⅰ)其中,Aib为氨基异丁酸,与前后氨基酸以酰胺键(肽键)连接;Xaa 13为Aib,Tyr或Ala;另有,(II)式中n为16或18;X 1与X 2同时为 或X 2为 同时X 1为
- 根据权利要求1所述的多肽衍生物,或其几何异构体、立体异构体、或其药学上可接受的盐,其特征在于所述的多肽衍生物为多肽主链有且仅有Xaa20位Lys其侧链ε-氨基以酰胺键形式连接含长脂肪酸修饰的支链,X 2为 同时X 1为
- 如权利要求1所述的多肽衍生物,或其几何异构体、立体异构体、或其药学上可接受的盐,所述的多肽衍生物为:
- 如权利要求1至3中任一项所述的多肽衍生物,或其几何异构体、立体异构体、或其药学上可接受的盐,其中氨基酸为L型,药学上可接受的盐优选为含钠的盐。
- 权利要求1至4中任一项所述的多肽衍生物,或其几何异构体、立体异构体、或其药学上可接受的盐的制备方法,其特征在于,包含支链片段合成、全保护多肽主链合成、支链偶联上肽树脂、裂解脱除肽链与侧链全保护、色谱纯化和冻干步骤或又包含固相法合成肽链、固相法将支链各模块逐次与肽树脂偶联、裂解除去保护基团与树脂挂载、色谱纯化和冻干步骤。
- 包含权利要求1至4中任一项所述的多肽衍生物、或几何异构体、或立体异构体、或其 药学上可接受的盐的药物组合物,所述的药物组合物还包括药学上可接受的载体。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或者权利要求6所述的药物组合物在治疗和/或预防下列至少一种疾病的药物中的应用:代谢综合征、肥胖、糖尿病、肥胖相关疾病和糖尿病相关疾病。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或权利要求6所述药物组合物在治疗和/或预防下列至少一种疾病的药物中的应用:胰岛素抵抗、糖耐量受损、前驱糖尿病、空腹血糖升高、Ⅱ型糖尿病、高血压、血脂异常(或这些代谢风险因素的组合)、动脉粥样硬化、动脉硬化、冠心病、外周动脉疾病和卒中等可能与肥胖有关的病症。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或权利要求6所述药物组合物在治疗和/或预防下列至少一种疾病的药物中的应用:肥胖相关炎症、肥胖相关胆囊疾病和肥胖诱发的睡眠呼吸暂停等肥胖相关疾病。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或者权利要求6所述的药物组合物在制备减少食物摄入量、减少β细胞凋亡、增加胰岛β细胞功能、增加β-细胞团和/或恢复葡萄糖对β-细胞的敏感性的药物中的应用。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或权利要求6所述药物组合物在治疗和/或预防下列至少一种疾病的药物中的应用:非酒精性单纯性脂肪肝(NAFL)、非酒精性脂肪性肝炎(NASH)及其相关肝硬化和肝细胞癌等疾病。
- 权利要求1至4中任一项所述多肽衍生物、或几何异构体、或立体异构体、或其药学上可接受的盐、或权利要求6所述药物组合物在治疗和/或预防下列至少一种疾病的药物中的应用:神经退行性疾病,包括阿尔茨海默症(AD)、帕金森症(PD)等。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021106088181 | 2021-06-01 | ||
CN202110608818 | 2021-06-01 | ||
PCT/CN2022/096109 WO2022253202A1 (zh) | 2021-06-01 | 2022-05-31 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117440964A true CN117440964A (zh) | 2024-01-23 |
Family
ID=84322810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280035107.2A Pending CN117440964A (zh) | 2021-06-01 | 2022-05-31 | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4345105A1 (zh) |
CN (1) | CN117440964A (zh) |
CA (1) | CA3222051A1 (zh) |
WO (1) | WO2022253202A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116891522A (zh) * | 2022-04-01 | 2023-10-17 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116970062B (zh) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | 一种超长效glp-1多肽衍生物及其制备方法和用途 |
CN116178523A (zh) * | 2022-12-27 | 2023-05-30 | 江苏诺泰澳赛诺生物制药股份有限公司 | 一种Tirzepatide的合成方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
KR102002783B1 (ko) * | 2011-06-10 | 2019-07-24 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용 |
TR201815338T4 (tr) * | 2012-05-03 | 2018-11-21 | Zealand Pharma As | Gıp-glp-1 dual agonist bileşikleri ve yöntemler. |
SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
US10093713B2 (en) * | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
MY197569A (en) * | 2018-07-23 | 2023-06-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
CN111825758A (zh) * | 2019-04-19 | 2020-10-27 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
-
2022
- 2022-05-31 WO PCT/CN2022/096109 patent/WO2022253202A1/zh active Application Filing
- 2022-05-31 CA CA3222051A patent/CA3222051A1/en active Pending
- 2022-05-31 EP EP22815247.6A patent/EP4345105A1/en active Pending
- 2022-05-31 CN CN202280035107.2A patent/CN117440964A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116891522A (zh) * | 2022-04-01 | 2023-10-17 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
EP4345105A1 (en) | 2024-04-03 |
WO2022253202A1 (zh) | 2022-12-08 |
CA3222051A1 (en) | 2022-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2015276203B2 (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
RU2492183C2 (ru) | Пептид, фармацевтическая композиция (варианты) и лекарственное средство на его основе, способ лечения и/или предупреждения диабета или заболеваний, сопутствующих ожирению, способ уменьшения аппетита, уменьшения потребления пищи, уменьшения потребления калорий, уменьшения массы тела и увеличения расхода энергии | |
DK2934567T3 (en) | EXENDIN-4 DERIVATIVES AS DOUBLE GLP1 / GIP OR TRIGONAL GLP1 / GIP / GLUCAGON AGONISTS | |
JP6898231B2 (ja) | Gipアゴニスト化合物及び方法 | |
CN112409460B (zh) | 一类glp-1/胰高血糖素受体双重激动剂及其应用 | |
KR102011924B1 (ko) | 인슐린 저항성에 대한 개선된 펩티드 제약 | |
TWI596110B (zh) | 新穎升糖素類似物 | |
EP1409006B1 (en) | Monodispersed mixtures and methods of treating diabetes | |
CN117440964A (zh) | 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途 | |
TW201410703A (zh) | 艾塞那肽-4(exendin-4)胜肽類似物 | |
NO328077B1 (no) | Anvendelse av en eksendin eller eksendinagonist for fremstilling av en farmasoytisk formulering. | |
CN116891522B (zh) | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 | |
JP2023071869A (ja) | グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト | |
KR102230368B1 (ko) | 아실화 옥신토모듈린 펩타이드 유사체 | |
CN116554299A (zh) | 长效glp-1多肽类似物及其制备方法和应用 | |
EP4353249A1 (en) | Multi-agonist and use thereof | |
WO2021227989A1 (zh) | 具有双受体激动作用的多肽衍生物及其用途 | |
CN116970062B (zh) | 一种超长效glp-1多肽衍生物及其制备方法和用途 | |
CN112608378A (zh) | 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用 | |
CN118085062A (zh) | 一种作为gcgr和glp-1r双受体激动剂的多肽衍生物及其制备方法和用途 | |
CN118108832A (zh) | 一种长效的类似胰淀素的多肽衍生物及其制备方法和用途 | |
CN115785249B (zh) | 一类glp-1类似物及其应用 | |
CN118056841A (zh) | 一种长效胰岛素衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |